Latest Period
Q4 2025
Security Snapshot
enGene Therapeutics Inc. - Common Shares (ENGN) Institutional Ownership
CUSIP: 29286M105
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
57
Shares (Excl. Options)
58,699,543
Price
$9.03
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Shares
- Symbol
- ENGN on Nasdaq
- Shares outstanding
- 67,348,192
- Price per share
- $6.76
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 58,699,543
- Total reported value
- $530,008,548
- % of total 13F portfolios
- 0%
- Share change
- +17,595,169
- Value change
- +$166,162,647
- Number of holders
- 57
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ENGN - enGene Therapeutics Inc. - Common Shares is tracked under CUSIP 29286M105.
- 57 institutions reported positions in Q4 2025.
- 9 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 57 to 4 between Q4 2025 and Q1 2026.
- Reported value moved from $530,008,548 to $2,812,373.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 57 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 29286M105?
CUSIP 29286M105 identifies ENGN - enGene Therapeutics Inc. - Common Shares in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29286M105:
Significant Owners of enGene Therapeutics Inc. - Common Shares (ENGN) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% | $47,123,411 | 6,770,605 | Perceptive Advisors LLC | 11 Nov 2025 | |||
| Invus Global Management, LLC | 7.8% | +25% | $35,511,355 | +$6,818,136 | 5,253,159 | +24% | Raymond Debbane | 31 Mar 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 7.1% | -28% | $39,984,449 | -$2,304,500 | 4,771,414 | -5.4% | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2025 |
| Deep Track Capital, LP | 6.7% | +58% | $30,048,631 | +$14,462,734 | 4,317,332 | +93% | Deep Track Capital, LP | 11 Nov 2025 |
| Cormorant Asset Management, LP | 6% | $33,520,000 | 4,000,000 | Cormorant Asset Management, LP | 31 Dec 2025 | |||
| Fonds de solidarite des travailleurs et des travailleuses du Quebec | 4.5% | $8,119,004 | 2,029,751 | Fonds de solidarite des travailleurs et des travailleuses du Quebec | 30 Sep 2024 | |||
| Adage Capital Management, L.P. | 3% | $6,115,072 | 1,528,768 | Adage Capital Management, L.P. | 31 Dec 2024 | |||
| Kynam Capital Management, LP | 2.2% | -76% | $12,510,485 | -$29,339,989 | 1,492,898 | -70% | Kynam Capital Management, LP | 31 Dec 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 1.8% | -68% | $3,781,608 | -$8,424,148 | 945,402 | -69% | BVF PARTNERS L P/IL | 27 Jan 2025 |
As of 31 Dec 2025, 57 institutional investors reported holding 58,699,543 shares of enGene Therapeutics Inc. - Common Shares (ENGN). This represents 87% of the company’s total 67,348,192 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of enGene Therapeutics Inc. - Common Shares (ENGN) together control 84% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FCPM III SERVICES B.V. | 14% | 9,632,561 | 0% | 11% | $86,982,026 |
| PERCEPTIVE ADVISORS LLC | 8.7% | 5,869,076 | +180% | 0.97% | $52,997,756 |
| VR ADVISER, LLC | 7.1% | 4,771,414 | -5.4% | 2.1% | $43,085,868 |
| Deep Track Capital, LP | 6.5% | 4,377,572 | +95% | 0.9% | $39,529,475 |
| Cormorant Asset Management, LP | 5.9% | 4,000,000 | +72% | 2% | $36,120,000 |
| Blue Owl Capital Holdings LP | 5% | 3,360,937 | +2.5% | 9.4% | $30,349,261 |
| Siren, L.L.C. | 5% | 3,336,264 | 0.9% | $30,126,464 | |
| BRAIDWELL LP | 4.6% | 3,131,319 | +38% | 0.9% | $28,275,811 |
| Nextech Invest, Ltd. | 3.2% | 2,124,943 | 1.9% | $19,188,235 | |
| JANUS HENDERSON GROUP PLC | 2.8% | 1,900,000 | 0.01% | $17,109,500 | |
| MPM BIOIMPACT LLC | 2.7% | 1,840,898 | +247% | 1.9% | $16,623,309 |
| MILLENNIUM MANAGEMENT LLC | 2.2% | 1,499,520 | +7214% | 0.01% | $13,540,666 |
| Kynam Capital Management, LP | 2.2% | 1,492,898 | -70% | 0.88% | $13,480,869 |
| FRANKLIN RESOURCES INC | 2.1% | 1,388,000 | +34% | 0% | $12,533,640 |
| Polar Capital Holdings Plc | 1.7% | 1,142,982 | 0.05% | $10,321,127 | |
| Vestal Point Capital, LP | 1.6% | 1,055,000 | +185% | 0.35% | $9,526,650 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.4% | 950,000 | 0.13% | $8,578,500 | |
| Omega Fund Management, LLC | 1.3% | 876,357 | +66% | 2.8% | $7,913,504 |
| SR One Capital Management, LP | 1.1% | 747,750 | 0% | 0.96% | $6,752,183 |
| MORGAN STANLEY | 1.1% | 718,485 | +65% | 0% | $6,487,919 |
| Affinity Asset Advisors, LLC | 0.96% | 643,370 | +736% | 0.42% | $5,809,631 |
| Point72 Asset Management, L.P. | 0.83% | 561,797 | -54% | 0.01% | $5,073,027 |
| Eversept Partners, LP | 0.68% | 455,835 | 0.23% | $4,116,190 | |
| Privium Fund Management B.V. | 0.52% | 352,087 | 0.59% | $3,179,346 | |
| MARSHALL WACE, LLP | 0.51% | 343,928 | 0% | 0% | $3,105,670 |
Institutional Holders of enGene Therapeutics Inc. - Common Shares (ENGN) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 412,977 | $2,812,373 | +$328,622 | $6.81 | 4 |
| 2025 Q4 | 58,699,543 | $530,008,548 | +$166,162,647 | $9.03 | 57 |
| 2025 Q3 | 40,858,497 | $279,063,473 | +$5,402,489 | $6.83 | 37 |
| 2025 Q2 | 40,420,485 | $147,130,372 | -$1,920,470 | $3.64 | 37 |
| 2025 Q1 | 40,941,351 | $183,416,794 | -$6,334,706 | $4.48 | 31 |
| 2024 Q4 | 41,304,528 | $274,675,480 | +$47,869,542 | $6.65 | 34 |
| 2024 Q3 | 34,293,391 | $227,693,885 | +$6,723,051 | $6.60 | 30 |
| 2024 Q2 | 32,608,601 | $307,109,469 | -$7,912,013 | $9.43 | 30 |
| 2024 Q1 | 31,657,538 | $536,055,932 | +$295,887,521 | $16.95 | 31 |
| 2023 Q4 | 14,187,864 | $130,941,207 | +$50,843,719 | $9.23 | 11 |